Abbot Financial Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Abbot Financial Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-337	Closed	-$232K	–	114
2022 Q3	$232K	Sell	337 -30	-8%	-$18.9K	0.17%	102
2022 Q2	$217K	Hold	367	–	–	0.13%	116
2022 Q1	$256K	Hold	367	–	–	0.13%	116
2021 Q4	$232K	Sell	367 -394	-52%	-$242K	0.1%	124
2021 Q3	$461K	Hold	761	–	–	0.21%	90
2021 Q2	$425K	Buy	761 +50	+7%	+$25.3K	0.19%	94
2021 Q1	$336K	Buy	711 +145	+26%	+$70.6K	0.15%	97
2020 Q4	$273K	Buy	+566	New	+$306K	0.16%	103

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Abbot Financial Management's REGN Position: Q4 2022 in Review

Abbot Financial Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 337 shares — an estimated $232K sold.

Abbot Financial Management first reported a position in REGN in Q4 2020 and held it in 8 quarters. The position peaked at $461K in Q3 2021. 1,159 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

Abbot Financial Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Abbot Financial Management sold 337 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $232K.
Abbot Financial Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 8 quarters.
Abbot Financial Management's Regeneron Pharmaceuticals position peaked at $461K in Q3 2021.
1,159 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Abbot Financial Management's 13F filing for Q4 2022, filed 9 Feb 2023.